{"id":745587,"date":"2017-02-24T16:00:00","date_gmt":"2017-02-24T16:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/in-first-phase-3-trial-mercks-investigational-inactivated-varicella-zoster-virus-vaccine-v212-reduced-the-incidence-of-confirmed-herpes-zoster-cases-by-an-estimated-64-percent-in-immunocom\/"},"modified":"2025-11-07T01:26:39","modified_gmt":"2025-11-07T06:26:39","slug":"in-first-phase-3-trial-mercks-investigational-inactivated-varicella-zoster-virus-vaccine-v212-reduced-the-incidence-of-confirmed-herpes-zoster-cases-by-an-estimated-64-percent-in-immunocom","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/in-first-phase-3-trial-mercks-investigational-inactivated-varicella-zoster-virus-vaccine-v212-reduced-the-incidence-of-confirmed-herpes-zoster-cases-by-an-estimated-64-percent-in-immunocom\/","title":{"rendered":"In First Phase 3 Trial, Merck\u2019s Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromised Subjects"},"content":{"rendered":"<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the first Phase 3 study results for V212, the company\u2019s<br \/>\n      investigational inactivated varicella zoster virus vaccine (VZV) for the<br \/>\n      prevention of herpes zoster or HZ, also known as shingles, in<br \/>\n      immunocompromised patients. This was a double-blind, randomized,<br \/>\n      placebo-controlled, multi-center trial to study safety, tolerability,<br \/>\n      efficacy and immunogenicity of inactivated VZV Vaccine in Recipients of<br \/>\n      Autologous Hematopoietic Stem Cell Transplants (auto-HSCT). In the<br \/>\n      trial, V212 met its primary endpoint and reduced the incidence of<br \/>\n      confirmed HZ cases by an estimated 64 percent (95% CI, 0.48, 0.75) in<br \/>\n      recipients of auto-HSCT. These results were presented today, as an oral<br \/>\n      presentation, at the combined annual meetings of the Center for<br \/>\n      International Blood &amp; Marrow Transplant Research (CIBMTR) and the<br \/>\n      American Society for Blood and Marrow Transplantation (ASBMT) during a<br \/>\n      \u201cBest Abstracts\u201d session in Orlando, Florida.\n    <\/p>\n<p>\n      Secondary endpoint findings from the study showed that V212 reduced the<br \/>\n      incidence of moderate-to-severe HZ pain by an estimated 69.5 percent,<br \/>\n      utilizing the Zoster Brief Pain Inventory (ZBPI) score. V212<br \/>\n      demonstrated an estimated 83.7 percent reduction of the incidence of<br \/>\n      post-herpetic neuralgia (PHN) beyond 90 days after onset of HZ. In the<br \/>\n      study PHN was defined as pain in the area of the HZ rash with a \u201cworst<br \/>\n      pain in the last 24 hours\u201d score of 3 or greater (on a 0 to 10 scale) on<br \/>\n      the ZBPI that persists or appears 90 days or beyond after HZ rash onset<br \/>\n      following auto-HSCT.\n    <\/p>\n<p>\n      In addition, V212 showed reduction of other HZ complications by an<br \/>\n      estimated 73.5 percent. These other complications included<br \/>\n      hospitalization or prolongation of hospitalization due to HZ;<br \/>\n      disseminated HZ (including disseminated HZ rash or VZV viremia);<br \/>\n      visceral HZ, ophthalmic HZ; neurological impairment due to HZ; or<br \/>\n      administration of intravenous acyclovir therapy for treatment of HZ post<br \/>\n      auto-HSCT.\n    <\/p>\n<p>\n      Because subjects receiving auto-HSCT are immunocompromised, they are at<br \/>\n      six-times greater risk of developing shingles than the general<br \/>\n      population. In 2014, an estimated 11,000 people underwent stem cell<br \/>\n      transplantation in the United States. ZOSTAVAX<sup> \u00ae<\/sup> (zoster<br \/>\n      vaccine live), the only approved vaccine indicated for the prevention of<br \/>\n      shingles in individuals 50 years of age or older, is contraindicated in<br \/>\n      immunocompromised patients. ZOSTAVAX is not indicated for the treatment<br \/>\n      of zoster or postherpetic neuralgia. ZOSTAVAX should not be used for<br \/>\n      prevention of primary varicella infection (Chickenpox).\n    <\/p>\n<p>\n      \u201cPatients undergoing auto-HSCT have an increased risk of HZ and<br \/>\n      associated complications due to impaired cellular immunity. These<br \/>\n      results indicate that V212 might offer a way to help reduce the risk of<br \/>\n      HZ and HZ-related complications in this vulnerable, immunocompromised<br \/>\n      patient population,\u201d said Eliav Barr, M.D., senior vice president, Merck<br \/>\n      Research Laboratories. \u201cWe look forward to exploring these data further<br \/>\n      and to reviewing the results of an additional Phase 3 study that is<br \/>\n      underway in immunocompromised patients with malignancies.\u201d\n    <\/p>\n<p>\n      <b>About the Study (NCT01229267)<\/b>\n    <\/p>\n<p>\n      The Phase 3 randomized, double-blind, placebo-controlled, multi-center<br \/>\n      trial included patients 18 years or older, undergoing auto-HSCT for<br \/>\n      malignancy or any other indication, with a history of varicella<br \/>\n      infection and\/or seropositive for VZV antibody. Subjects had no<br \/>\n      malignancy with more than two disease relapses (except Hodgkin<br \/>\n      lymphoma), no planned tandem transplants, no previous VZV vaccination,<br \/>\n      no HZ infection within the previous year, and no intended antiviral<br \/>\n      prophylaxis for &gt;6 months after auto-HSCT (antiviral prophylaxis for &lt;6<br \/>\n      months was allowed).\n    <\/p>\n<p>\n      Eligible subjects (n=1,230) were randomly assigned to receive a 4-dose<br \/>\n      regimen of V212 from a consistency lot (a lot having a targeted potency<br \/>\n      as required by regulators in order to demonstrate that the vaccine can<br \/>\n      be manufactured consistently), a high-antigen lot (a lot having a higher<br \/>\n      antigen potency added to assess further the safety profile of V212), or<br \/>\n      placebo. Randomization was stratified by age (younger than 50 years vs.<br \/>\n      older than 50 years) and by intended duration of post-transplant<br \/>\n      antiviral prophylaxis (\u22643 months vs. &gt;3 to 6 months).\n    <\/p>\n<p>\n      Dose 1 of V212 or placebo was given within approximately 30 days before<br \/>\n      auto-HSCT, and doses 2, 3, and 4 were given approximately 30, 60, and 90<br \/>\n      days after auto-HSCT. Subjects were followed for the duration of the<br \/>\n      study for efficacy with cases of HZ confirmed by PCR and\/or adjudicated<br \/>\n      by a blinded data monitoring committee. The average follow-up time for<br \/>\n      HZ surveillance was approximately 2.3 years (median: 2.6 years) post<br \/>\n      vaccination.\n    <\/p>\n<p>\n      The most common systemic adverse events observed in both the vaccine and<br \/>\n      placebo arms of the study at a incidence rate of 15 percent or more in<br \/>\n      either group, included diarrhea, nausea, pyrexia, mucosal inflammation,<br \/>\n      thrombocytopenia, febrile neutropenia, vomiting, anemia, neutropenia,<br \/>\n      decreased appetite, fatigue, hypokalemia, and constipation.\n    <\/p>\n<p>\n      Serious adverse events occurred in 216 (32.9%) subjects receiving the<br \/>\n      consistency lot or high-antigen lot and in 181 (32.7%) subjects<br \/>\n      receiving placebo for up to 28 days after the fourth vaccination dose.<br \/>\n      The most frequent serious adverse event observed was febrile neutropenia<br \/>\n      observed in 5.3 percent of the vaccine group and 4.9 percent in the<br \/>\n      placebo group. Serious vaccine-related adverse events occurred in 5<br \/>\n      (0.8%) subjects receiving consistency lot or high-antigen lot and in 5<br \/>\n      (0.9%) subjects receiving placebo.\n    <\/p>\n<p>\n      <b>About V212<\/b>\n    <\/p>\n<p>\n      V212 is Merck\u2019s investigational inactivated VZV vaccine for the<br \/>\n      prevention of HZ and HZ-related complications in immunocompromised<br \/>\n      subjects age 18 years and above. The Phase 3 trial in auto-HSCT<br \/>\n      recipients has been completed. Another Phase 3 trial in subjects with<br \/>\n      malignancies is ongoing.\n    <\/p>\n<p>\n      <b>About ZOSTAVAX<\/b><br \/>\n<sup><br \/>\n<b>\u00ae <\/b><br \/>\n<\/sup>(zoster vaccine live)\n    <\/p>\n<p>\n      ZOSTAVAX is a live attenuated virus vaccine indicated for prevention of<br \/>\n      herpes zoster (shingles) in individuals 50 years of age and older.<br \/>\n      ZOSTAVAX is not indicated for the treatment of zoster or postherpetic<br \/>\n      neuralgia. ZOSTAVAX should not be used for prevention of primary<br \/>\n      varicella infection (Chickenpox).\n    <\/p>\n<p>\n      <b>Select Safety Information<\/b>\n    <\/p>\n<p>\n      Vaccination with ZOSTAVAX does not result in protection of all vaccine<br \/>\n      recipients.\n    <\/p>\n<p>\n      ZOSTAVAX is contraindicated in: persons with a history of anaphylactic<br \/>\n      or anaphylactoid reaction to gelatin, neomycin, or any other component<br \/>\n      of the vaccine; persons with a history of primary or acquired<br \/>\n      immunodeficiencies; persons on immunosuppressive therapy; pregnant women<br \/>\n      or women of childbearing age.\n    <\/p>\n<p>\n      A reduced immune response to ZOSTAVAX was observed in individuals who<br \/>\n      received concurrent administration of PNEUMOVAX<sup>\u00ae<\/sup>23<br \/>\n      (Pneumococcal Vaccine Polyvalent) and ZOSTAVAX compared with individuals<br \/>\n      who received these vaccines 4 weeks apart. Consider administration of<br \/>\n      the two vaccines separated by at least 4 weeks.\n    <\/p>\n<p>\n      Serious vaccine-related adverse reactions that have occurred following<br \/>\n      vaccination with ZOSTAVAX include asthma exacerbation and polymyalgia<br \/>\n      rheumatica. Other serious adverse events reported following vaccination<br \/>\n      with ZOSTAVAX (zoster vaccine live) include cardiovascular events<br \/>\n      (congestive heart failure, pulmonary edema). Common adverse reactions<br \/>\n      occurring in \u22651% of vaccinated individuals during clinical trials<br \/>\n      include injection-site reactions (erythema, pain\/tenderness, swelling,<br \/>\n      hematoma, pruritus, warmth) and headache.\n    <\/p>\n<p>\n      Transmission of vaccine virus may occur between vaccinees and<br \/>\n      susceptible contacts.\n    <\/p>\n<p>\n      Deferral should be considered in acute illness (for example, in the<br \/>\n      presence of fever) or in subjects with active untreated tuberculosis.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies, and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51516037&amp;newsitemid=20170224005651&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=3794305daedc51235f03acafa8dfbf12\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51516037&amp;newsitemid=20170224005651&amp;lan=en-US&amp;anchor=Twitter&amp;index=2&amp;md5=2d86db96dc38dcab9fa5c3e74535ef73\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51516037&amp;newsitemid=20170224005651&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=0bcd4ec5479540e0007bd7216d0b1266\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51516037&amp;newsitemid=20170224005651&amp;lan=en-US&amp;anchor=YouTube&amp;index=4&amp;md5=cd1003d39ddfe9ea6e4d3fc1fae3268d\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51516037&amp;newsitemid=20170224005651&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=2242bf58a6c211898711116c43f65e5b\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51516037&amp;newsitemid=20170224005651&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=6&amp;md5=e978c3aa8f7f00f39eaaeebc76677c80\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for ZOSTAVAX at <\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzostavax%2Fzostavax_pi2.pdf&amp;esheet=51516037&amp;newsitemid=20170224005651&amp;lan=en-US&amp;anchor=https%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzostavax%2Fzostavax_pi2.pdf&amp;index=7&amp;md5=57fe252c986181bdc549067e0af41db5\" rel=\"nofollow\"><br \/>\n<b>https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/z\/zostavax\/zostavax_pi2.pdf<\/b><br \/>\n<\/a><br \/>\n<b><br \/>\n      and Patient Information for ZOSTAVAX at <\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzostavax%2Fzostavax_ppi.pdf&amp;esheet=51516037&amp;newsitemid=20170224005651&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzostavax%2Fzostavax_ppi.pdf&amp;index=8&amp;md5=852e43f5d18798450695cc0e61578317\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/z\/zostavax\/zostavax_ppi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20170224005651r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/><br \/>\n<span class=\"bwct31415\" \/><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Skip        Irvine, 267-305-0338<br \/>or<br \/>Investors:<br \/>Amy Klug, 908-740-1898<br \/>or<br \/>Michael        DeCarbo, 908-740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first Phase 3 study results for V212, the company\u2019s investigational inactivated varicella zoster virus vaccine (VZV) for the prevention of herpes zoster or HZ, also known as shingles, in immunocompromised patients. This was a double-blind, randomized, placebo-controlled, multi-center trial to study safety, tolerability, efficacy and immunogenicity of inactivated VZV Vaccine in Recipients of Autologous Hematopoietic Stem Cell Transplants (auto-HSCT). In the trial, V212 met its primary endpoint and reduced the incidence of confirmed HZ cases by an estimated 64 percent (95% CI, 0.48, 0.75) in recipients of auto-HSCT. These results were presented today, as an oral presentation, at the combined annual meetings of the Center for International Blood &amp; Marrow Transplant Research (CIBMTR) and the American Society for Blood and Marrow Transplantation (ASBMT) during a \u201cBest Abstracts\u201d session in Orlando,<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-745587","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>In First Phase 3 Trial, Merck\u2019s Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromised Subjects - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/in-first-phase-3-trial-mercks-investigational-inactivated-varicella-zoster-virus-vaccine-v212-reduced-the-incidence-of-confirmed-herpes-zoster-cases-by-an-estimated-64-percent-in-immunocom\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"In First Phase 3 Trial, Merck\u2019s Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromised Subjects - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first Phase 3 study results for V212, the company\u2019s investigational inactivated varicella zoster virus vaccine (VZV) for the prevention of herpes zoster or HZ, also known as shingles, in immunocompromised patients. This was a double-blind, randomized, placebo-controlled, multi-center trial to study safety, tolerability, efficacy and immunogenicity of inactivated VZV Vaccine in Recipients of Autologous Hematopoietic Stem Cell Transplants (auto-HSCT). In the trial, V212 met its primary endpoint and reduced the incidence of confirmed HZ cases by an estimated 64 percent (95% CI, 0.48, 0.75) in recipients of auto-HSCT. These results were presented today, as an oral presentation, at the combined annual meetings of the Center for International Blood &amp; Marrow Transplant Research (CIBMTR) and the American Society for Blood and Marrow Transplantation (ASBMT) during a \u201cBest Abstracts\u201d session in Orlando,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/in-first-phase-3-trial-mercks-investigational-inactivated-varicella-zoster-virus-vaccine-v212-reduced-the-incidence-of-confirmed-herpes-zoster-cases-by-an-estimated-64-percent-in-immunocom\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/in-first-phase-3-trial-mercks-investigational-inactivated-varicella-zoster-virus-vaccine-v212-reduced-the-incidence-of-confirmed-herpes-zoster-cases-by-an-estimated-64-percent-in-immunocom\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/in-first-phase-3-trial-mercks-investigational-inactivated-varicella-zoster-virus-vaccine-v212-reduced-the-incidence-of-confirmed-herpes-zoster-cases-by-an-estimated-64-percent-in-immunocom\\\/\",\"name\":\"In First Phase 3 Trial, Merck\u2019s Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromised Subjects - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2017-02-24T16:00:00+00:00\",\"dateModified\":\"2025-11-07T06:26:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/in-first-phase-3-trial-mercks-investigational-inactivated-varicella-zoster-virus-vaccine-v212-reduced-the-incidence-of-confirmed-herpes-zoster-cases-by-an-estimated-64-percent-in-immunocom\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/in-first-phase-3-trial-mercks-investigational-inactivated-varicella-zoster-virus-vaccine-v212-reduced-the-incidence-of-confirmed-herpes-zoster-cases-by-an-estimated-64-percent-in-immunocom\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/in-first-phase-3-trial-mercks-investigational-inactivated-varicella-zoster-virus-vaccine-v212-reduced-the-incidence-of-confirmed-herpes-zoster-cases-by-an-estimated-64-percent-in-immunocom\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"In First Phase 3 Trial, Merck\u2019s Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromised Subjects\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"In First Phase 3 Trial, Merck\u2019s Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromised Subjects - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/in-first-phase-3-trial-mercks-investigational-inactivated-varicella-zoster-virus-vaccine-v212-reduced-the-incidence-of-confirmed-herpes-zoster-cases-by-an-estimated-64-percent-in-immunocom\/","og_locale":"en_US","og_type":"article","og_title":"In First Phase 3 Trial, Merck\u2019s Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromised Subjects - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first Phase 3 study results for V212, the company\u2019s investigational inactivated varicella zoster virus vaccine (VZV) for the prevention of herpes zoster or HZ, also known as shingles, in immunocompromised patients. This was a double-blind, randomized, placebo-controlled, multi-center trial to study safety, tolerability, efficacy and immunogenicity of inactivated VZV Vaccine in Recipients of Autologous Hematopoietic Stem Cell Transplants (auto-HSCT). In the trial, V212 met its primary endpoint and reduced the incidence of confirmed HZ cases by an estimated 64 percent (95% CI, 0.48, 0.75) in recipients of auto-HSCT. These results were presented today, as an oral presentation, at the combined annual meetings of the Center for International Blood &amp; Marrow Transplant Research (CIBMTR) and the American Society for Blood and Marrow Transplantation (ASBMT) during a \u201cBest Abstracts\u201d session in Orlando,","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/in-first-phase-3-trial-mercks-investigational-inactivated-varicella-zoster-virus-vaccine-v212-reduced-the-incidence-of-confirmed-herpes-zoster-cases-by-an-estimated-64-percent-in-immunocom\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:39+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/in-first-phase-3-trial-mercks-investigational-inactivated-varicella-zoster-virus-vaccine-v212-reduced-the-incidence-of-confirmed-herpes-zoster-cases-by-an-estimated-64-percent-in-immunocom\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/in-first-phase-3-trial-mercks-investigational-inactivated-varicella-zoster-virus-vaccine-v212-reduced-the-incidence-of-confirmed-herpes-zoster-cases-by-an-estimated-64-percent-in-immunocom\/","name":"In First Phase 3 Trial, Merck\u2019s Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromised Subjects - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2017-02-24T16:00:00+00:00","dateModified":"2025-11-07T06:26:39+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/in-first-phase-3-trial-mercks-investigational-inactivated-varicella-zoster-virus-vaccine-v212-reduced-the-incidence-of-confirmed-herpes-zoster-cases-by-an-estimated-64-percent-in-immunocom\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/in-first-phase-3-trial-mercks-investigational-inactivated-varicella-zoster-virus-vaccine-v212-reduced-the-incidence-of-confirmed-herpes-zoster-cases-by-an-estimated-64-percent-in-immunocom\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/in-first-phase-3-trial-mercks-investigational-inactivated-varicella-zoster-virus-vaccine-v212-reduced-the-incidence-of-confirmed-herpes-zoster-cases-by-an-estimated-64-percent-in-immunocom\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"In First Phase 3 Trial, Merck\u2019s Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromised Subjects"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"25021ad6-05d3-454c-b265-6fea4313a682","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745587","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745587\/revisions"}],"predecessor-version":[{"id":3674956,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745587\/revisions\/3674956"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745587"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745587"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}